Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Department of Obstetrics and Gynecology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Int J Med Sci. 2021 Sep 24;18(16):3712-3717. doi: 10.7150/ijms.64658. eCollection 2021.
Evaluate the prognostic value of neutrophil-lymphocyte ratio (NMR), platelet-lymphocyte ratio (PLR), and monocyte-lymphocyte ratio (MLR) in patients with non-endometrioid endometrial cancer. Laboratory and clinicopathological data from 118 patients with non-endometrioid endometrial cancer who underwent surgical resection between January 2010 and December 2019 were reviewed. NLR, PLR and MLR were analyzed for correlations with recurrence and survival. The receiver operating characteristic (ROC) curves were generated for the NLR, PLR, and MLR. Optimal cut-off values were determined as the points at which the Youden index (sensitivity + specificity - 1) was maximal. Based on the results of the ROC curve analysis, the patients were grouped into high MLR and low MLR groups. Recurrence rate, disease-free survival, and overall survival were compared between the two groups. The prognostic factors were investigated using univariate and multivariate Cox proportional hazards model. The optimal cut-off value of MLR was 0.191 (AUC, 0.718; < 0.001). Significantly more patients in the high MLR group experienced recurrence (60.3% vs. 15.6%, < 0.0001) and cancer-related deaths (46.6% vs. 13.3%, = 0.003). In multivariate analysis, advanced stage and high MLR were independent prognostic factors for disease-free survival and overall survival. Elevated MLR was significantly associated poor clinical outcomes in patients with non endometrioid endometrial cancer. Our findings suggest that MLR may be clinically reliable and useful as an independent prognostic marker for patients with non-endometrioid endometrial cancer.
评估中性粒细胞-淋巴细胞比值（NLR）、血小板-淋巴细胞比值（PLR）和单核细胞-淋巴细胞比值（MLR）在非子宫内膜样子宫内膜癌患者中的预后价值。回顾分析 2010 年 1 月至 2019 年 12 月期间接受手术切除的 118 例非子宫内膜样子宫内膜癌患者的实验室和临床病理数据。分析 NLR、PLR 和 MLR 与复发和生存的相关性。绘制 NLR、PLR 和 MLR 的受试者工作特征（ROC）曲线。最佳截断值定义为 Youden 指数（灵敏度+特异性-1）最大的点。根据 ROC 曲线分析结果，将患者分为高 MLR 组和低 MLR 组。比较两组患者的复发率、无病生存率和总生存率。采用单因素和多因素 Cox 比例风险模型探讨预后因素。MLR 的最佳截断值为 0.191（AUC，0.718； < 0.001）。高 MLR 组患者的复发率（60.3%比 15.6%， < 0.0001）和癌症相关死亡率（46.6%比 13.3%，=0.003）明显更高。多因素分析显示，晚期和高 MLR 是无病生存和总生存的独立预后因素。高 MLR 与非子宫内膜样子宫内膜癌患者的不良临床结局显著相关。研究结果表明，MLR 可能是一种可靠的临床指标，可作为非子宫内膜样子宫内膜癌患者的独立预后标志物。
